Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Neurology. 2006 Jan 24;66(2):250-2. doi: 10.1212/01.wnl.0000194318.74946.b6.

Abstract

In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adult
  • Biological Availability
  • Biomarkers / metabolism
  • Brain / metabolism*
  • Creatine / adverse effects
  • Creatine / pharmacokinetics*
  • Creatine / therapeutic use*
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / antagonists & inhibitors
  • Deoxyguanosine / blood
  • Double-Blind Method
  • Female
  • Humans
  • Huntington Disease / blood
  • Huntington Disease / drug therapy*
  • Huntington Disease / metabolism*
  • Male
  • Middle Aged

Substances

  • Biomarkers
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine
  • Creatine